IP Library Granted Patent US 11,304,997
Granted Patent B2
US 11,304,997 · App. 16/715,758 · Granted Apr 19, 2022

HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell

Inventors: Tomoya Miyakawa (Tokyo, JP); Masaaki Oka (Yamaguchi, JP); Shoichi Hazama (Yamaguchi, JP); Koji Tamada (Yamaguchi, JP); Keiko Udaka (Kochi, JP)
Assignee: CYTLIMIC INC.
A61K39/001176A61K38/00A61K39/00A61K39/0011A61K47/50C07K7/06C12N15/09A61K2039/545
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,304,997
App. No.
16/715,758
Granted
Apr 19, 2022
Kind
B2
Abstract

The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.

Claims (5)

1. A method for inducing an immune response in a subject suffering from cancer, comprising a step of administrating to the subject a peptide consisting of the amino acid sequence of SEQ ID NO: 7.

2. The method according to claim 1 , wherein the peptide can bind to one or more types of HLA molecules.

3. A method for inducing an immune response in a subject suffering from cancer, comprising a step of administrating to the subject a pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 7 and a pharmaceutically acceptable formulation component.

4. The method according to claim 3 , wherein the pharmaceutical composition is in the form of a vaccine.

5. The method according to claim 4 , wherein the peptide can bind to one or more types of HLA molecules.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2023
From: CYTLIMIC INC.
To: NEC CORPORATION
Reel/Frame 062357/0203 →
Priority Claims (1)
JP 2014-206730 · Oct 7, 2014 · national
Continuity (2)
Division 15516918
Related Publication 20200121772A1 · Apr 23, 2020